Tumor Biology

, Volume 37, Issue 6, pp 7501–7505 | Cite as

RETRACTED ARTICLE: Overexpression of interleukins IL-17 and IL-8 with poor prognosis in colorectal cancer induces metastasis

  • Mohsen Mohammadi
  • Maria Kaghazian
  • Omid Rahmani
  • Koorosh Ahmadi
  • Elham Hatami
  • Katayoun Ziari
  • Amir Talebreza
Original Article


Current evidences indicated that a group of soluble mediators called chemokines is involved in tumor growth and metastasis. The association of IL-8 with tumor cell migration was previously found, and its expression was related to angiogenesis, tumor progression, and metastasis in many kinds of carcinomas in human and animal models. Furthermore, it has been showed that IL-17 plays its role as either a proteome of tumor progression or antitumor indifferent cancer models. To investigate the messenger RNA (mRNA) expressions of IL-8 and IL-17 in patients with colorectal cancer (CRC) and non-tumor tissue, quantitative real-time PCR was used in the study. Our results showed that expression of IL-8 mRNA was significantly increased in tumor tissues (mean ± SD 3.84 ± 0.08) compared with adjacent normal mucosa (mean ± SD 1.17 ± 0.75, P = 0.001). Furthermore, a higher expression of IL-17 mRNA was found in tumor tissues (mean ± SD 2.73 ± 0.69) when compared with normal tissues (mean ± SD 1.06 ± 0.07, P = 0.001). Our findings indicated that advanced tumor-node-metastasis (TNM) stage (P = 0.024) and histological grade (poorly differentiated, P = 0.013) and distant metastasis (P = 0.001) were correlated with expression of IL-8. Moreover, high expression of IL-17 showed significant association with early stage CRC (TNM) (P = 0.038). In conclusion, the expression of IL-8 and IL-17 mRNAs was significantly increased in tumor tissues compared with adjacent normal tissues. We found that advanced TNM stage and histological grade and distant metastasis were correlated with expression of IL-8, while high expression of IL-17 showed significant association with early stage CRC (TNM) stage and overexpression of IL-8 may be associated with progression of CRC.


IL-17 IL-8 Colorectal cancer PCR Expression 


Compliance with ethical standard

Conflicts of interest



  1. 1.
    Tan E, Tilney H, Thompson M, Smith J, Tekkis PP. Association of coloproctology of Great Britain and Ireland, The United Kingdom national bowel cancer project—epidemiology and surgical risk in the elderly. Eur J Cancer. 2007;43:2285–94.CrossRefPubMedGoogle Scholar
  2. 2.
    Ries LAG, Eisner MP. SEER cancer statistics review, 1973–1997. Bethesda: National Cancer Institute; 2000.Google Scholar
  3. 3.
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30.CrossRefPubMedGoogle Scholar
  4. 4.
    Doll D, Keller L, Maak M, Boulesteix AL, Siewert JR, Holzmann B. Differential expression of the chemokines GRO-2, GRO-3, and interleukin-8 in colon cancer and their impact on metastatic disease and survival. Int J Color Dis. 2010;25(5):573–81.CrossRefGoogle Scholar
  5. 5.
    Sparmann A, Bar-Sagi D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell. 2004;6:447–58.CrossRefPubMedGoogle Scholar
  6. 6.
    Huang D, Ding Y, Zhou M, Rini BI, Petillo D, Qian CN. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res. 2010;70:1063–71.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol. 2000;18:217–42.CrossRefPubMedGoogle Scholar
  8. 8.
    Inoue K, Slaton JW, Eve BY, Kim SJ, Perrotte P, Balbay MD, et al. Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin Cancer Res. 2000;6:2104–19.PubMedGoogle Scholar
  9. 9.
    Zhu YM, Webster SJ, Flower D, Woll PJ. Interleukin-8/CXCL8 is a growth factor for human lung cancer cells. Br J Cancer. 2004;91:1970–6.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Kitadai Y, Haruma K, Mukaida N, Ohmoto Y, Matsutani N, Yasui W, et al. Regulation of disease-progression genes in human gastric carcinoma cells by interleukin 8. Clin Cancer Res. 2000;6:2735–40.PubMedGoogle Scholar
  11. 11.
    Maeda S, Omata M. Inflammation and cancer: role of nuclear factor-kappaB activation. Cancer Sci. 2008;99(5):836–42.CrossRefPubMedGoogle Scholar
  12. 12.
    Vandercappellen J, Van Damme J, Struyf S. The role of CXC chemokines and their receptors in cancer. Cancer Lett. 2008;267(2):226–44.CrossRefPubMedGoogle Scholar
  13. 13.
    Masuya D, Huang C, Liu D, Kameyama K, Hayashi E, Yamauchi A. The intratumoral expression of vascular endothelial growth factor and interleukin-8 associated with angiogenesis in nonsmall cell lung carcinoma patients. Cancer. 2001;92(10):2628–38.CrossRefPubMedGoogle Scholar
  14. 14.
    Huang S, Mills L, Mian B, Tellez C, McCarty M, Yang XD. Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am J Pathol. 2002;161(1):125–34.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Cui G, Yuan A, Goll R, Florholmen J. IL-17A in the tumor microenvironment of the human colorectal adenoma–carcinoma sequence. Scand J Gastroenterol. 2012;47:1304–12.CrossRefPubMedGoogle Scholar
  16. 16.
    Zhang JP, Yan J, Xu J, Pang XH, Chen MS, Li L. Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol. 2009;50:980–9.CrossRefPubMedGoogle Scholar
  17. 17.
    He D, Li H, Yusuf N, Elmets CA, Li J, Mountz JD. IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells. J Immunol. 2010;184:2281–8.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Martin-Orozco N, Muranski P, Chung Y, Yang XO, Yamazaki T, Lu S. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity. 2009;31:787–98.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Kryczek I, Wei S, Szeliga W, Vatan L, Zou W. Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood. 2009;114:357–9.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Takamori H, Oades ZG, Hoch OC, Burger M, Schraufstatter IU. Autocrine growth effect of IL-8 and GROalpha on a human pancreatic cancer cell line, capan-1. Pancrea. 2000;21:52–6.CrossRefGoogle Scholar
  21. 21.
    Brew R, Erikson JS, West DC, Kinsella AR, Slavin J, Christmas SE. Interleukin-8 as an autocrine growth factor for human colon carcinoma cells in vitro. Cytokine. 2000;12:78–85.CrossRefPubMedGoogle Scholar
  22. 22.
    Lang K, Niggemann B, Zanker KS, Entschladen F. Signal processing in migrating t24 human bladder carcinoma cells: role of the autocrine interleukin-8 loop. Int J Cancer. 2002;99:673–80.CrossRefPubMedGoogle Scholar
  23. 23.
    Maxwell PJ, Gallagher R, Seaton A, Wilson C, Scullin P, Pettigrew J. Hif-1 and nf-kappab-mediated upregulation of cxcr1 and cxcr2 expression promotes cell survival in hypoxic prostate cancer cells. Oncogene. 2007;26:7333–45.CrossRefPubMedGoogle Scholar
  24. 24.
    Rubie C, Frick VO, Pfeil S, Wagner M, Kollmar O, Kopp B, et al. Correlation of IL-8 with induction, progression and metastatic potential of colorectal cancer. World J Gastroenterol. 2007;13(37):4996–5002.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    An H, Zhu Y, Xie H, Liu Y, Liu W, Fu Q, Ye D, Xu J. Increased expression of interleukin-8 is an independent indicator of poor prognosis in clear-cell renal cell carcinoma. Tumour Biol. 2015.Google Scholar
  26. 26.
    Lurje G, Husain H, Power DG, Yang D, Groshen S, Pohl A, et al. Genetic variations in angiogenesis pathway genes associated with clinical outcome in localized gastric adenocarcinoma. Ann Oncol. 2010;21(1):78–86. doi: 10.1093/annonc/mdp280.
  27. 27.
    Schultheis AM, Lurje G, Rhodes KE, Zhang W, Yang D, Garcia AA, et al. Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab. Clin Cancer Res. 2008;14:7554–63.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Ning Y, Manegold PC, Hong YK. Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models. Int J Cancer. 2011;128(9):2038–49.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Baier PK, Eggstein S, Wolff-Vorbeck G, Baumgartner U, Hopt UT. Chemokines in human colorectal carcinoma. Anticancer Res. 2005;25:3581–4.PubMedGoogle Scholar
  30. 30.
    Terada H, Urano T, Konno H. Association of interleukin-8 and plasminogen activator system in the progression of colorectal cancer. Eur Surg Res. 2005;37:166–72.CrossRefPubMedGoogle Scholar
  31. 31.
    Li A, Dubey S, Varney ML, Dave BJ, Singh RK. IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol. 2003;170:3369–76.CrossRefPubMedGoogle Scholar
  32. 32.
    Mian BM, Dinney CP, Bermejo CE, Sweeney P, Tellez C, Yang XD. Fully human anti-interleukin 8 antibody inhibits tumor growth in orthotopic bladder cancer xenografts via down-regulation of matrix metalloproteases and nuclear factor-kappab. Clin Cancer Res Off J Am Assoc Cancer Res. 2003;9:3167–75.Google Scholar
  33. 33.
    Balbay MD, Pettaway CA, Kuniyasu H, Inoue K, Ramirez E, Li E, et al. Highly metastatic human prostate cancer growing within the prostate of athymic mice overexpresses vascular endothelial growth factor. Clin Cancer Res. 1999;5:783–9.PubMedGoogle Scholar
  34. 34.
    Schadendorf D, Fichtner I, Makki A, Alijagic S, Kupper M, Mrowietz U, et al. Metastatic potential of human melanoma cells in nude mice–characterisation of phenotype, cytokine secretion and tumour-associated antigens. Br J Cancer. 1996;74:194–9.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Lin Y, Xu J, Su H, Zhong W, Yuan Y, Yu Z, et al. Interleukin-17 is a favorable prognostic marker for colorectal cancer. Clin Transl Oncol. 2015;17(1):50–6.CrossRefPubMedGoogle Scholar
  36. 36.
    Petanidis S, Anestakis D, Argyraki M, Hadzopoulou-Cladaras M, Salifoglou A. Differential expression of il-17, 22 and 23 in the progression of colorectal cancer in patients with k-ras mutation: ras signal inhibition and crosstalk with GM-CSF and IFN-gamma. PLoS One. 2013;8, e73616.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Liu J, Duan Y, Cheng X, Chen X, Xie W, Long H. IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma. Biochem Biophys Res Commun. 2011;407:348–54.CrossRefPubMedGoogle Scholar
  38. 38.
    Le Gouvello S, Bastuji-Garin S. High prevalence of Foxp3 and IL17 in MMR-proficient colorectal carcinomas. Gut. 2008;57:772–9.CrossRefPubMedGoogle Scholar
  39. 39.
    Steiner GE, Newman ME, Paikl D. Expression and function of proinflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate. Prostate. 2003;56:171–82.CrossRefPubMedGoogle Scholar
  40. 40.
    Chen X, Wan J, Liu J. Increased IL-17-producing cells correlate with poor survival and lymphangiogenesis in NSCLC patients. Lung Cancer. 2010;69:348–354.7.CrossRefPubMedGoogle Scholar
  41. 41.
    Miyahara Y, Odunsi K, Chen W, Peng G, Matsuzaki J, Wang RF. Generation and regulation of human CD4 + IL-17-producing T cells in ovarian cancer. Proc Natl Acad Sci U S A. 2008;105:15505–10.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Mohsen Mohammadi
    • 1
  • Maria Kaghazian
    • 2
  • Omid Rahmani
    • 3
  • Koorosh Ahmadi
    • 4
  • Elham Hatami
    • 5
  • Katayoun Ziari
    • 3
  • Amir Talebreza
    • 6
  1. 1.Department of Pharmaceutical Biotechnology, Faculty of PharmacyLorestan University of Medical SciencesKhorramabadIran
  2. 2.Department of BiologyJundishapur University of Medical SciencesAhvazIran
  3. 3.Department of PathologyBe’sat Hospital, AJA University of Medical SciencesTehranIran
  4. 4.Department of Emergency MedicineAlborz University of Medical SciencesKarajIran
  5. 5.Department of PathologyLoghman Hakim HospitalSarakhsIran
  6. 6.Department of SurgeryAJA University of Medical SciencesTehranIran

Personalised recommendations